Landos Biopharma Secures $60M Financing, Continues BT-11 Development for IBD
News
Landos Biopharma’s investigational BT-11 therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is continuing testing in Phase 2 clinical trials — some of which are, ... Read more